Akihito Tsuji
Overview
Explore the profile of Akihito Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
3960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Moriwaki T, Nishina T, Sakai Y, Yamamoto Y, Shimada M, Ishida H, et al.
Jpn J Clin Oncol
. 2022 Apr;
52(7):725-734.
PMID: 35470391
Objective: Many clinical trials for older patients with metastatic colorectal cancer have been conducted, and fluoropyrimidine and bevacizumab are standard treatments. However, the relationship between age and the efficacy and...
22.
Hatachi Y, Mohan S, Kotake T, Satake H, Okita Y, Yasui H, et al.
Cancer Diagn Progn
. 2022 Apr;
2(1):101-106.
PMID: 35400007
Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy...
23.
Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, et al.
JCO Precis Oncol
. 2022 Feb;
6:e2100383.
PMID: 35188805
Purpose: Circulating tumor DNA (ctDNA) genotyping may guide targeted therapy for patients with advanced GI cancers. However, no studies have validated ctDNA genotyping for microsatellite instability (MSI) assessment in comparison...
24.
Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, et al.
JCO Precis Oncol
. 2022 Jan;
4:898-911.
PMID: 35050760
Purpose: Several trials have evaluated the efficacy of rechallenge treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with metastatic colorectal cancer (mCRC). A recent trial indicated...
25.
Folprecht G, Martinelli E, Mazard T, Modest D, Tsuji A, Esser R, et al.
Cancer Treat Rev
. 2021 Nov;
102:102301.
PMID: 34839118
Doublet or triplet chemotherapy regimens in combination with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti-vascular endothelial growth factor mAb bevacizumab, are...
26.
Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, et al.
Target Oncol
. 2021 Oct;
16(6):753-760.
PMID: 34718946
Background: Regorafenib and trifluridine/tipiracil are standard third-line chemotherapies for colorectal cancer patients, but their efficacy is limited. Anti-epidermal growth factor receptor antibody rechallenge has been reported to be promising for...
27.
Okuyama H, Kagawa Y, Masuishi T, Mishima S, Shirasu H, Ando K, et al.
Int J Clin Oncol
. 2021 Sep;
26(11):2025-2028.
PMID: 34476649
Background: An infusion-related reaction (IRR) is a well-known adverse event related to monoclonal antibodies, and antihistamine premedication is recommended to prevent IRRs. Ramucirumab plus FOLFIRI therapy is the standard second-line...
28.
Sun J, Shen L, Shah M, Enzinger P, Adenis A, Doi T, et al.
Lancet
. 2021 Aug;
398(10302):759-771.
PMID: 34454674
Background: First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity of pembrolizumab plus chemotherapy versus chemotherapy alone as...
29.
Jogo T, Nakamura Y, Shitara K, Bando H, Yasui H, Esaki T, et al.
Clin Cancer Res
. 2021 Aug;
27(20):5619-5627.
PMID: 34376535
Purpose: amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting...
30.
Hayuka K, Okuyama H, Murakami A, Okita Y, Nishiuchi T, Okano K, et al.
Chemotherapy
. 2021 Jul;
66(3):58-64.
PMID: 34284397
Introduction: Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established as first-line treatment, but they have not been confirmed as...